by James R. Berenson, MD, Carol Ann Huff, MD, Paul G. Richardson, MD
Choosing a salvage treatment regimen in cases of relapsed/refractory multiple myeloma is challenging and complicated. It relies on the best use of ......READ MORE
by James R. Berenson, MD, Carol Ann Huff, MD, Paul G. Richardson, MD
Several novel therapies have been approved by the US Food and Drug Administration for relapsed/refractory multiple myeloma, including the immunomod......READ MORE
Use of triplet combination therapy in multiple myeloma—particularly the immunomodulatory drug (IMiD)–proteasome inhibitor (PI) triplets—relates to ......READ MORE
While most patients with multiple myeloma will achieve disease control with autologous stem cell transplant (ASCT), virtually all of these individu......READ MORE
Owing to significant bone pain, vulnerability to infection, fatigue, and other symptomatology related—and unrelated—to multiple myeloma, the diseas......READ MORE
Optimizing the care of older patients with multiple myeloma involves striking a balance between efficacy and toxicity. It also involves a deep unde......READ MORE
